PMID- 23371457
OWN - NLM
STAT- MEDLINE
DCOM- 20130920
LR  - 20211021
IS  - 1993-0402 (Electronic)
IS  - 1672-0415 (Linking)
VI  - 19
IP  - 2
DP  - 2013 Feb
TI  - The efficacy and safety of Jitongning Capsule () in patients with ankylosing 
      spondylitis.
PG  - 98-103
LID - 10.1007/s11655-012-1212-x [doi]
AB  - OBJECTIVE: To confirm the efficacy and safety of Jitongning Capsule in the 
      treatment of ankylosing spondylitis (AS). METHODS: A total of 120 AS patients 
      with early-intermediate were randomly and equally assigned to Jitongning Capsule 
      group and sulfasalazine group. Jitongning Capsule was orally taken 4.5 g per day 
      and sulfasalazine was orally taken 2 g daily for 12 months. The primary endpoint 
      was the proportion of patients achieving the Assessment in Ankylosing Spondylitis 
      20 (ASAS 20), secondary end points included Bath Ankylosing Spondylitis Disease 
      Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), 
      Bath Ankylosing Spondylitis Metrology Index (BASMI), patient's global assessment 
      by VAS rating, spinal pain, general pain and night pain, erythrocyte 
      sedimentation rate (ESR) and C-reactive protein (CRP). Tumor necrosis factor-alpha 
      (TNF-alpha), interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) in the peripheral blood 
      mononuclear cells (PBMC) of AS patients were measured. RESULTS: A total of 111 
      patients completed the study. There were 58 patients in Jitongning group and 53 
      patients in sulfasalazine group. Both drugs showed mild and occasional side 
      effects. After treated by Jitongning Capsule and sulfasalazine, the proportion of 
      ASAS20 responders at 12 month was 72.41% (42/58) and 67.92% (36/53) respectively. 
      Both Jitongning Capsule and sulfasalazine treatment induced significant decrease 
      in the proportion of CD4(+)T cell and CD8(+)T cell expressing TNF-alpha and IFN-gamma at 
      12-month of treatment compared with baseline values (P<0.05). CONCLUSION: 
      Jitongning Capsule are effective in a setting close to real-life medical care 
      with a sustained improvement in signs and symptoms of AS, and reduce cytokine 
      levels in PBMC. It showed comparable effects to sulfasalazine.
FAU - Wang, Yan-Yan
AU  - Wang YY
AD  - Department of Rheumatology, Chinese PLA General Hospital, Beijing, China.
FAU - Lu, Hui
AU  - Lu H
FAU - Zhao, Zheng
AU  - Zhao Z
FAU - Huang, Feng
AU  - Huang F
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20130131
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (jitongning)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Blood Sedimentation
MH  - C-Reactive Protein/metabolism
MH  - CD4-Positive T-Lymphocytes/drug effects/metabolism
MH  - CD8-Positive T-Lymphocytes/drug effects/metabolism
MH  - Drugs, Chinese Herbal/*adverse effects/*therapeutic use
MH  - Endpoint Determination
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Interleukin-4/metabolism
MH  - Male
MH  - Middle Aged
MH  - Spondylitis, Ankylosing/blood/*drug therapy/immunology
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Young Adult
EDAT- 2013/02/02 06:00
MHDA- 2013/09/21 06:00
CRDT- 2013/02/02 06:00
PHST- 2011/04/03 00:00 [received]
PHST- 2013/02/02 06:00 [entrez]
PHST- 2013/02/02 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
AID - 10.1007/s11655-012-1212-x [doi]
PST - ppublish
SO  - Chin J Integr Med. 2013 Feb;19(2):98-103. doi: 10.1007/s11655-012-1212-x. Epub 
      2013 Jan 31.